These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 30196651)

  • 21. Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies.
    Tang W; Xu Q; Hong T; Tong G; Feng W; Shen S; Bi Y; Zhu D
    Diabetes Metab Res Rev; 2016 Feb; 32(2):200-16. PubMed ID: 26381272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trigonelline attenuates hepatic complications and molecular alterations in high-fat high-fructose diet-induced insulin resistance in rats.
    Afifi NA; Ramadan A; Erian EY; Saleh DO; Sedik AA; Badawi M; El Hotaby W
    Can J Physiol Pharmacol; 2017 Apr; 95(4):427-436. PubMed ID: 28157387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of synbiotic food consumption on metabolic status of diabetic patients: a double-blind randomized cross-over controlled clinical trial.
    Asemi Z; Khorrami-Rad A; Alizadeh SA; Shakeri H; Esmaillzadeh A
    Clin Nutr; 2014 Apr; 33(2):198-203. PubMed ID: 23786900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of probiotics and synbiotics on blood glucose: a systematic review and meta-analysis of controlled trials.
    Nikbakht E; Khalesi S; Singh I; Williams LT; West NP; Colson N
    Eur J Nutr; 2018 Feb; 57(1):95-106. PubMed ID: 27590729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus.
    Koyanagawa N; Miyoshi H; Ono K; Nakamura A; Cho KY; Yamamoto K; Takano Y; Dan-Noura M; Atsumi T
    Endocr J; 2016 Aug; 63(8):747-53. PubMed ID: 27321385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the Effects of Mitiglinide and Glibenclamide Administered in Combination with the Dipeptidyl Peptidase-IV Inhibitor Sitagliptin in Rats with Streptozotocin-Nicotinamide-Induced Type 2 Diabetes.
    Akahane K; Ojima K; Yokoyama A; Inoue T; Kiguchi S; Tatemichi S; Takeda H; Kobayashi M
    Drug Res (Stuttg); 2017 Jul; 67(7):396-403. PubMed ID: 28486736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: Results of a randomized controlled trial.
    Göke R; Eschenbach P; Dütting ED
    Diabetes Metab; 2015 Jun; 41(3):244-7. PubMed ID: 25457473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes.
    Kato H; Nagai Y; Ohta A; Tenjin A; Nakamura Y; Tsukiyama H; Sasaki Y; Fukuda H; Ohshige T; Terashima Y; Sada Y; Kondo A; Sasaoka T; Tanaka Y
    Diabetes Res Clin Pract; 2015 Jul; 109(1):199-205. PubMed ID: 25934525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
    Peng XV; Marcinak JF; Raanan MG; Cao C
    Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial.
    Chen S; Zhao X; Ran L; Wan J; Wang X; Qin Y; Shu F; Gao Y; Yuan L; Zhang Q; Mi M
    Dig Liver Dis; 2015 Mar; 47(3):226-32. PubMed ID: 25577300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short and Long Term Effects of a DPP-4 Inhibitor Versus Bedtime NPH Insulin as ADD-ON Therapy in Patients with Type 2 Diabetes.
    da Silva GM; Nogueira KC; Fukui RT; Correia MR; Dos Santos RF; da Silva ME
    Curr Pharm Des; 2016; 22(44):6716-6721. PubMed ID: 27928958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of Sitagliptin and Insulin against Type 2 Diabetes Mellitus with Neuropathy in Rats: Neuroprotection and Role of Oxidative and Inflammation Stress.
    Kelany ME; Hakami TM; Omar AH; Abdallah MA
    Pharmacology; 2016; 98(5-6):242-250. PubMed ID: 27449930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of synbiotic supplementation on insulin resistance/sensitivity, lipid profile and total antioxidant capacity in women with gestational diabetes mellitus: A randomized double blind placebo controlled clinical trial.
    Nabhani Z; Hezaveh SJG; Razmpoosh E; Asghari-Jafarabadi M; Gargari BP
    Diabetes Res Clin Pract; 2018 Apr; 138():149-157. PubMed ID: 29432772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
    Cho MS; Kim SY; Suk KT; Kim BY
    J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis.
    Jung YA; Choi YK; Jung GS; Seo HY; Kim HS; Jang BK; Kim JG; Lee IK; Kim MK; Park KG
    Diabetes Res Clin Pract; 2014 Jul; 105(1):47-57. PubMed ID: 24842243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relationship between insulin resistance, metabolic syndrome and nonalcoholic fatty liver disease in non-obese non-diabetic Turkish individuals: A pilot study.
    Erkan G; Sayın I; Polat FB; Çorakçı A; Ataç GK; Değertekin H
    Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():63-8. PubMed ID: 25910371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of sitagliptin on energy metabolism and brown adipose tissue in overweight individuals with prediabetes: a randomised placebo-controlled trial.
    Nahon KJ; Doornink F; Straat ME; Botani K; Martinez-Tellez B; Abreu-Vieira G; van Klinken JB; Voortman GJ; Friesema ECH; Ruiz JR; van Velden FHP; de Geus-Oei LF; Smit F; Pereira Arias-Bouda LM; Berbée JFP; Jazet IM; Boon MR; Rensen PCN
    Diabetologia; 2018 Nov; 61(11):2386-2397. PubMed ID: 30145664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.
    van Genugten RE; van Raalte DH; Muskiet MH; Heymans MW; Pouwels PJ; Ouwens DM; Mari A; Diamant M
    Eur J Endocrinol; 2014 Mar; 170(3):429-39. PubMed ID: 24297090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of sitagliptin, a DPP-4 inhibitor, against DENA-induced liver cancer in rats mediated via NF-κB activation and inflammatory cytokines.
    Jiang W; Wen D; Cheng Z; Yang Y; Zheng G; Yin F
    J Biochem Mol Toxicol; 2018 Dec; 32(12):e22220. PubMed ID: 30218586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perioperative synbiotic therapy in elderly patients undergoing gastroenterological surgery: a prospective, randomized control trial.
    Okazaki M; Matsukuma S; Suto R; Miyazaki K; Hidaka M; Matsuo M; Noshima S; Zempo N; Asahara T; Nomoto K
    Nutrition; 2013 Oct; 29(10):1224-30. PubMed ID: 23867209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.